Dashboard
Adherence
Adherence: 00000000
Operational Dashboard
Generated an hour ago · Core + HCP Portal + Patient Portal
Needs attention: 30 SLA breach(es) · 13 escalations.
Hub Urgent22 vs last wk
4330 SLA breach(es)
HCP Waiting7 vs last wk
85 enrolment submission(s)
Patient Waiting16 vs last wk
163 change request(s)
New Patients
154
Enrolments
116
Open Cases
110
Total Cases
134
Open Tasks
16
Pending Faxes
0
Escalated
13
SLA Breaches
30
Fax Intake
Received
0
Missing Info
0
Ready
0
In Progress
7
Processed
16
Rejected
0
Enrolments
Referral Volume
116
Active
91
Pending
23
Cancelled
1
Completion Rate
78.4%
Total
116
Tasks
Total
20
Pending
13
In Progress
3
Completed
2
Overdue
18
Cancelled
2
Investigations
Total
8
Pending
1
In Progress
1
Completed
6
Covered
1
Not Covered
0
Authorisations
Total PAs
25
Approved
4
Denied
19
Pending
1
Approval Rate
17.4%
Appeals
1
Fulfilment
Triage Total
3
Triage Routed
1
Triage Complete
2
Shipments
3
Delivered
1
Pending Ship
1
Outreach
Messages Sent
70
Delivered
66
Failed
4
Delivery Rate
94.3%
Active Campaigns
1
Done Campaigns
1
Quality
Escalations
13
SLA Breaches
30
Cancelled Cases
0
Open Cases
110
Overdue Tasks
18
Rejected Faxes
0
HCP Portal
Active 7d
1
Total Users
3
Pending Referrals
5
Pending Uploads
7
Open Tasks
1
Unread Msgs
2
Patient Portal
Active 7d
1
Total Users
13
Change Requests
3
Open Tasks
9
Unread Msgs
4
Adoption
8%
Adherence Monitoring
All Statuses
All Risk Tiers
| Patient | Therapy | Status | Risk | PDC (90d) | Doses | Gap Days | Open Barriers | Last Dose | Next Follow-Up | Assigned |
|---|---|---|---|---|---|---|---|---|---|---|
Patient | Therapy | Status | Risk | PDC (90d) | Doses | Gap Days | Open Barriers | Last Dose | Next Follow-Up | Assigned |
| Patricia Davis | Briumvi (ublituximab) J3590 | ON THERAPY | LOW (15) | 92.5% | 4 | 0 | 0 | 14d ago | Apr 27 | hub-agent-1 |
| Elizabeth Taylor | Keytruda (pembrolizumab) J9271 | AT RISK | HIGH (62) | 68% | 5(2 missed) | 18 | 2 | 44d ago | Apr 16 | hub-agent-2 |
| Jennifer Martinez | Opdivo (nivolumab) J9299 | NOT STARTED | -- | -- | 0 | 0 | 0 | -- | -- | -- |
| John Alexander | Not specified | NOT STARTED | -- | -- | 0 | 0 | 0 | -- | -- | -- |
Page 1 · 4 items (all records)
Per page:
25
Adherence Record — Keytruda (pembrolizumab)
AT RISK
Risk: HIGH (62/100)
Started: Oct 15, 2025
PDC: 68%
| Total Doses | 5 | Missed | 2 | Gap Days | 18 |
|---|---|---|---|---|---|
| Open Barriers | 2 | Regimen | infusion / every 4 weeks | ||
No risk scores available for this case
Timeline
Medication & Dosing
Barriers & Interventions
Outcomes
Analytics
- Intervention: transportation assistplannedApr 15, 2026 — Arrange medical transportation service for infusion appointments.
- Intervention: side effect managementin_progressApr 8, 2026 — Coordinating with oncologist on anti-nausea pre-medication protocol.
- Gap: infusion delayhighApr 6, 2026 — 7 days | Severity: high | Open
- Barrier: side effectsin_progressMar 29, 2026 — Patient reports fatigue and nausea after infusions, considering discontinuation.
- Barrier: transportationopenMar 24, 2026 — Patient lacks reliable transportation to infusion center. Lives 45 minutes from ...
- Intervention: outreach callcompletedMar 14, 2026 — Called patient to discuss importance of staying on therapy schedule. | Outcome: successful
- infusion — Keytruda (pembrolizumab)infusionMar 9, 2026 — 7 days late
- Gap: infusion delaymoderateMar 2, 2026 — 7 days | Severity: moderate | Resolved
- infusion — Keytruda (pembrolizumab)infusionFeb 22, 2026 —
- infusion — Keytruda (pembrolizumab)infusionJan 18, 2026 — 7 days late
- infusion — Keytruda (pembrolizumab)infusionDec 14, 2025 —
- infusion — Keytruda (pembrolizumab)infusionNov 14, 2025 —
Open Barriers
2
Resolved
0
Interventions
3
Success Rate
100%
Barriers (2)
| Category | Description | Status | Severity | Identified | Resolved | Actions |
|---|---|---|---|---|---|---|
Category | Description | Status | Severity | Identified | Resolved | Actions |
| side effects | Patient reports fatigue and nausea after infusions, considering discontinuation. | in progress | moderate | Mar 29, 2026 | - | |
| transportation | Patient lacks reliable transportation to infusion center. Lives 45 minutes from nearest site. | open | high | Mar 24, 2026 | - |
Interventions (3)
| Type | Description | Status | Outcome | Planned | Completed | Actions |
|---|---|---|---|---|---|---|
Type | Description | Status | Outcome | Planned | Completed | Actions |
| transportation assist | Arrange medical transportation service for infusion appointments. | planned | - | Apr 15, 2026 | - | |
| side effect management | Coordinating with oncologist on anti-nausea pre-medication protocol. | in progress | - | Apr 8, 2026 | - | |
| outreach call | Called patient to discuss importance of staying on therapy schedule. | completed | successful | Mar 14, 2026 | Mar 14, 2026 |
Therapy Status
AT RISK
Therapy Details
TherapyKeytruda (pembrolizumab) | CodeJ9271 | Start DateOct 15, 2025 |
End Date- | Total Doses Administered5 | Missed Doses2 |
Last DoseMar 9, 2026 | Next Follow-UpApr 16, 2026 | |
Adherence Metrics at Outcome
PDC (90-day)68% | PDC (180-day)72.5% | PDC (365-day)- |
MPR- | On-Time Rate- | Risk Score62/100 |
Gap Days18 | Open Barriers2 | |
Risk Score Trend
- Risk Score
PDC Trend
- PDC 180-day
- PDC 365-day
- PDC 90-day
Interventions by Type
Barriers by Category
Cohort Comparison (Programme Average)
Total Patients2 | Avg PDC (90-day)68% | Avg Risk Score62/100 |
Avg Gap Days9 | ||
Risk Distribution: high: 1